Claims:

1. Use of a lysine acetyltransferase 6 (KAT6) inhibitor in the manufacture of a medicament for use in combination with:

a) a cyclin-dependent kinase 4 (CDK4) inhibitor; or

b) an antiestrogen; or

c) a CDK4 inhibitor and an antiestrogen;

for treating breast cancer,

wherein the KAT6 inhibitor is 2-methoxy-*N*-{4-methoxy-6-[(1*H*-pyrazol-1-yl)methyl]-1,2-benzoxazol-3-yl}benzene-1-sulfonamide, or a pharmaceutically acceptable salt thereof,

wherein the antiestrogen is fulvestrant or letrozole, and

wherein the CDK4 inhibitor is either 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1*H*-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-*threo*-pentitol, or a pharmaceutically acceptable salt thereof or palbociclib, or a pharmaceutically acceptable salt thereof.

2. Use of a lysine acetyltransferase 6 (KAT6) inhibitor in the manufacture of a medicament, optionally in combination with a CDK4 inhibitor, for treating breast cancer that is resistant to treatment with endocrine therapy, wherein the CDK4 inhibitor is palbociclib, or a pharmaceutically acceptable salt thereof.

3. The use of claim 1, wherein the CDK4 inhibitor is 1,5-anhydro-3-({5-chloro-4-[4-fluoro-2-(2-hydroxypropan-2-yl)-1-(propan-2-yl)-1*H*-benzimidazol-6-yl]pyrimidin-2-yl}amino)-2,3-dideoxy-D-*threo*-pentitol, or a pharmaceutically acceptable salt thereof.

4. The use of claim 1 or claim 2, wherein the CDK4 inhibitor is palbociclib, or a pharmaceutically acceptable salt thereof.

5. The use of claim 1, wherein the antiestrogen is fulvestrant.

6. The use of any one of claims 1 to 5, wherein the patient is human.

7. The use of claim 1 or claim 2, wherein the breast cancer is locally advanced or metastatic estrogen receptor positive (ER+) breast cancer.

8. The use of claim 1 or claim 2, wherein the breast cancer is locally advanced or metastatic estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) breast cancer.